3.5.1.98 (1R,5S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-6-oxabicyclo[3.1.1]heptane-3-carboxamide i.e. BRD7232, inhibition kinetics; i.e. BRD7232, possesses kinetic selectivity for isozyme HDAC1 versus HDAC2, inhibition kinetics; inhibition kinetics 237596 3.5.1.98 (2E)-3-[1,2-bis(2-phenylethyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide - 72579 3.5.1.98 (2E)-3-[1-benzyl-2-(2-phenylethyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide - 72580 3.5.1.98 (2E)-3-[1-benzyl-2-(2-phenylethyl)-1H-benzimidazol-6-yl]-N-hydroxyprop-2-enamide - 72581 3.5.1.98 (2E)-3-[1-ethyl-2-(2-phenylethyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide - 72582 3.5.1.98 (2E)-3-[1-[2-(diethylamino)ethyl]-2-(2-phenylethyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide - 72583 3.5.1.98 (2E)-3-[1-[3-(dimethylamino)-2,2-dimethylpropyl]-2-(2-phenylethyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide - 72500 3.5.1.98 (2E)-3-[1-[3-(dimethylamino)propyl]-2-(2-phenylethyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide - 72584 3.5.1.98 (2E)-3-[1-[4-(dimethylamino)butyl]-2-(2-phenylethyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide - 72585 3.5.1.98 (2E)-3-[2-cyclohexyl-1-(3-hydroxypropyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide - 72586 3.5.1.98 (2E)-3-[2-[(benzyloxy)methyl]-1-(3-hydroxypropyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide - 72587 3.5.1.98 (2E)-3-[4-([[2-(3a,7a-dihydro-1H-indol-3-yl)ethyl](2-hydroxyethyl)amino]methyl)phenyl]-N-hydroxyprop-2-enamide - 82208 3.5.1.98 (2E)-N-(2-aminophenyl)-3-(4-{1-[(2-hydroxyethyl)amino]-2-oxo-2-[4-(trifluoromethyl)anilino]ethyl}phenyl)prop-2-enamide - 204502 3.5.1.98 (2E)-N-(2-aminophenyl)-3-(4-{1-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-2-oxo-2-[4-(trifluoromethyl)anilino]ethyl}phenyl)prop-2-enamide - 204503 3.5.1.98 (2E)-N-(2-aminophenyl)-3-[2-(2-phenylethyl)-1-(pyridin-2-ylmethyl)-1H-benzimidazol-5-yl]prop-2-enamide - 72588 3.5.1.98 (2E)-N-(2-aminophenyl)-3-[4-(1-{[2-(morpholin-4-yl)ethyl]amino}-2-oxo-2-[4-(trifluoromethyl)anilino]ethyl)phenyl]prop-2-enamide - 204504 3.5.1.98 (2E)-N-(2-aminophenyl)-3-{4-[2-(4-bromoanilino)-1-(3-hydroxypyrrolidin-1-yl)-2-oxoethyl]phenyl}prop-2-enamide - 204505 3.5.1.98 (2E)-N-hydroxy-3-naphthalen-1-ylprop-2-enamide HDAC8-selective inhibitor 72589 3.5.1.98 (2E)-N-hydroxy-3-[1-(2-morpholin-4-ylethyl)-2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide - 72590 3.5.1.98 (2E)-N-hydroxy-3-[1-(3-hydroxypropyl)-1H-benzimidazol-5-yl]prop-2-enamide - 72591 3.5.1.98 (2E)-N-hydroxy-3-[1-(3-hydroxypropyl)-2-(1-methylethyl)-1H-benzimidazol-5-yl]prop-2-enamide - 71185 3.5.1.98 (2E)-N-hydroxy-3-[1-(3-hydroxypropyl)-2-(2-methylpropyl)-1H-benzimidazol-5-yl]prop-2-enamide - 72592 3.5.1.98 (2E)-N-hydroxy-3-[1-(3-hydroxypropyl)-2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide - 72593 3.5.1.98 (2E)-N-hydroxy-3-[1-(3-hydroxypropyl)-2-(2-phenylpropyl)-1H-benzimidazol-5-yl]prop-2-enamide - 72594 3.5.1.98 (2E)-N-hydroxy-3-[1-(3-hydroxypropyl)-2-octyl-1H-benzimidazol-5-yl]prop-2-enamide - 72595 3.5.1.98 (2E)-N-hydroxy-3-[1-(3-hydroxypropyl)-2-thiophen-3-yl-1H-benzimidazol-5-yl]prop-2-enamide - 72596 3.5.1.98 (2E)-N-hydroxy-3-[1-(3-methoxypropyl)-2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide - 72597 3.5.1.98 (2E)-N-hydroxy-3-[1-(3-morpholin-4-ylpropyl)-2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide - 72598 3.5.1.98 (2E)-N-hydroxy-3-[1-methyl-2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide - 72599 3.5.1.98 (2E)-N-hydroxy-3-[1-[3-(1H-imidazol-1-yl)propyl]-2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide - 72600 3.5.1.98 (2E)-N-hydroxy-3-[1-[3-(2-oxopyrrolidin-1-yl)propyl]-2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide - 72508 3.5.1.98 (2E)-N-hydroxy-3-[2-(2-phenylethyl)-1-(2-piperidin-1-ylethyl)-1H-benzimidazol-5-yl]prop-2-enamide - 71107 3.5.1.98 (2E)-N-hydroxy-3-[2-(2-phenylethyl)-1-(2-pyrrolidin-1-ylethyl)-1H-benzimidazol-5-yl]prop-2-enamide - 72601 3.5.1.98 (2E)-N-hydroxy-3-[2-(2-phenylethyl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazol-5-yl]prop-2-enamide - 72602 3.5.1.98 (2E)-N-hydroxy-3-[2-(2-phenylethyl)-1-(3-pyrrolidin-1-ylpropyl)-1H-benzimidazol-5-yl]prop-2-enamide - 72603 3.5.1.98 (2E)-N-hydroxy-3-[2-(2-phenylethyl)-1-(pyridin-2-ylmethyl)-1H-benzimidazol-5-yl]prop-2-enamide - 72604 3.5.1.98 (2E)-N-hydroxy-3-[2-(2-phenylethyl)-1-propyl-1H-benzimidazol-5-yl]prop-2-enamide - 72605 3.5.1.98 (2E)-N-hydroxy-3-[2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide - 72606 3.5.1.98 (2E)-N-hydroxy-3-[2-[(4-methoxyphenyl)sulfonyl]-2,3-dihydro-1H-isoindol-5-yl]prop-2-enamide anti-proliferative activity in human HCT116 cell line, IC50 0.93 microM 55597 3.5.1.98 (2E)-N-hydroxy-3-[2-[2-(1H-indol-3-yl)ethyl]-2,3-dihydro-1H-isoindol-5-yl]prop-2-enamide anti-proliferative activity in human HCT116 cell line, IC50 0.22 microM 55596 3.5.1.98 (2E)-N-hydroxy-3-[2-[2-(2-methyl-1H-indol-3-yl)ethyl]-2,3-dihydro-1H-isoindol-5-yl]prop-2-enamide anti-proliferative activity in human HCT116 cell line, IC50 0.1042microM. Compound has a reasonable combination of potency, solubility and human microsomal stability to justify further investigation 55431 3.5.1.98 (2E)-N-hydroxy-3-[2-[2-(pyrazolo[1,5-a]pyridin-3-yl)ethyl]-2,3-dihydro-1H-isoindol-5-yl]prop-2-enamide anti-proliferative activity in human HCT116 cell line, IC50 0.53 microM. Compound has a reasonable combination of potency, solubility and human microsomal stability to justify further investigation 55433 3.5.1.98 (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide - 39096 3.5.1.98 (2R)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-2-carboxamide - 237704 3.5.1.98 (2S)-2-(acetylamino)-3-[3-[(2S)-2-[[(2S)-2-ammonio-7-(hydroxyamino)-7-oxoheptanoyl]amino]-3-methoxy-3-oxopropyl]phenyl]propanoate - 37047 3.5.1.98 (2S)-8-oxo-2-[(3-piperidin-1-ylpropanoyl)amino]-N-quinolin-3-ylnonanamide - 72703 3.5.1.98 (2S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-2-carboxamide - 237767 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]-2-fluorophenyl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide - 204582 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-benzyl-N-(4-chlorophenyl)pyrrolidine-3-carboxamide - 204583 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(3-methylphenyl)pyrrolidine-3-carboxamide - 204584 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(4-methylphenyl)pyrrolidine-3-carboxamide - 204585 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(6-methylpyridin-3-yl)pyrrolidine-3-carboxamide - 204586 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(piperidin-1-yl)pyrrolidine-3-carboxamide - 204587 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(propan-2-yl)pyrrolidine-3-carboxamide - 204588 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(pyridin-2-yl)pyrrolidine-3-carboxamide - 204589 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(pyridin-3-yl)pyrrolidine-3-carboxamide - 204590 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(pyridin-4-yl)pyrrolidine-3-carboxamide - 204591 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-phenylpyrrolidine-3-carboxamide - 204592 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-[4-(propan-2-yl)phenyl]pyrrolidine-3-carboxamide - 204593 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-[4-(trifluoromethyl)phenyl]pyrrolidine-3-carboxamide - 204594 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(2,4-difluorophenyl)-1-methylpyrrolidine-3-carboxamide - 204595 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(2-chloro-4-fluorophenyl)-1-methylpyrrolidine-3-carboxamide - 204596 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(2-fluorophenyl)-1-methylpyrrolidine-3-carboxamide - 204597 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3,4-dichlorophenyl)-1-methylpyrrolidine-3-carboxamide - 204598 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3,4-difluorophenyl)-1-methylpyrrolidine-3-carboxamide - 204599 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3-bromo-4-fluorophenyl)-1-methylpyrrolidine-3-carboxamide - 204600 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3-chloro-4-fluorophenyl)-1-methylpyrrolidine-3-carboxamide - 204601 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3-chlorophenyl)-1-methylpyrrolidine-3-carboxamide - 204602 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3-fluorophenyl)-1-methylpyrrolidine-3-carboxamide - 204603 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3-methoxyphenyl)-1-methylpyrrolidine-3-carboxamide - 204604 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-bromophenyl)-1-methylpyrrolidine-3-carboxamide - 204605 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chloro-3-methylphenyl)-1-methylpyrrolidine-3-carboxamide - 204606 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2,2,2-trifluoroethyl)pyrrolidine-3-carboxamide - 204607 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2,2-difluoroethyl)pyrrolidine-3-carboxamide - 204608 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2,2-dimethylpropyl)pyrrolidine-3-carboxamide - 204609 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2-fluoroethyl)pyrrolidine-3-carboxamide - 204610 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2-hydroxy-2-methylpropyl)pyrrolidine-3-carboxamide - 204611 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2-hydroxyethyl)pyrrolidine-3-carboxamide - 204612 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2-methoxyethyl)pyrrolidine-3-carboxamide - 204613 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(3-hydroxy-2,2-dimethylpropyl)pyrrolidine-3-carboxamide - 204614 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(cyanomethyl)pyrrolidine-3-carboxamide - 204615 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(oxan-4-yl)pyrrolidine-3-carboxamide - 204616 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(propan-2-yl)pyrrolidine-3-carboxamide - 204617 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(pyrimidin-2-yl)pyrrolidine-3-carboxamide - 204618 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-cyclobutylpyrrolidine-3-carboxamide - 204619 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-ethylpyrrolidine-3-carboxamide - 204620 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide - 204621 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-cyanophenyl)-1-methylpyrrolidine-3-carboxamide - 204622 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-cyclopropylphenyl)-1-methylpyrrolidine-3-carboxamide - 204623 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-fluoro-3-methylphenyl)-1-methylpyrrolidine-3-carboxamide - 204624 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-fluorophenyl)-1-methylpyrrolidine-3-carboxamide - 204625 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-methoxyphenyl)-1-methylpyrrolidine-3-carboxamide - 204626 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(5-chloropyridin-2-yl)-1-methylpyrrolidine-3-carboxamide - 204627 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-cyclopentyl-1-methylpyrrolidine-3-carboxamide - 204628 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-cyclopropyl-1-methylpyrrolidine-3-carboxamide - 204629 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N~3~-(4-chlorophenyl)-N~1~,N~1~-diethylpyrrolidine-1,3-dicarboxamide - 204630 3.5.1.98 (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N~3~-(4-chlorophenyl)-N~1~-ethylpyrrolidine-1,3-dicarboxamide - 204631 3.5.1.98 (3R)-4-{5-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]pyrazin-2-yl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide - 204632 3.5.1.98 (3R)-4-{5-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]pyridin-2-yl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide - 204633 3.5.1.98 (3R)-4-{6-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]pyridazin-3-yl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide - 204634 3.5.1.98 (3R)-4-{6-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]pyridin-3-yl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide - 204635 3.5.1.98 (3R,4S)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide - 204637 3.5.1.98 (3S)-3-{[(3S)-3-{[(benzyloxy)carbonyl]amino}-3-cyclopropylpropanoyl]amino}-2-oxo-5-phenylpentyl acetate - 151848 3.5.1.98 (3S,15R,20aS)-15-methyl-3-[(1E)-4-sulfanylbut-1-en-1-yl]-3,4,6,7,14,15,18,19,20,20a-decahydro-1H,5H,16H-11,8:15,12-di(azeno)pyrrolo[2,1-c][1,8,12,4,15]oxadithiadiazacyclooctadecine-1,5,16-trione - 10177 3.5.1.98 (3S,6S,10S,14S)-3-(1H-indol-3-ylmethyl)-10-methyl-14-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,11-tetraazacyclotetradecane-2,5,8,12-tetrone - 6999 3.5.1.98 (3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9,10-dimethyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone - 7000 3.5.1.98 (3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9-methyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone - 7001 3.5.1.98 (3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-3-(6-oxooctyl)decahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecine-1,4,7,11(8H)-tetrone - 7002 3.5.1.98 (4E)-N-(2-aminophenyl)-5-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]pent-4-enamide - 10178 3.5.1.98 (4Z)-6-[(5R,8S,11R)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]hex-4-enoic acid - 10179 3.5.1.98 (5E)-N-(2-aminophenyl)-6-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]hex-5-enamide - 10180 3.5.1.98 (5R,8S,11S)-5-methyl-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione - 10181 3.5.1.98 (5R,8S,11S)-5-methyl-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3-thia-7,14,20,21-tetraazatricyclo[14.3.1.1-2,5]henicosa-1(20),2(21),16,18-tetraene-6,9,13-trione - 10182 3.5.1.98 (5R,8S,11S)-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione - 10183 3.5.1.98 (5S,8R,11R)-5-methyl-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione - 10184 3.5.1.98 (5S,8S,11S,5'S,8'S,11'S)-11,11'-[disulfanediyldi(1E)but-1-ene-4,1-diyl]bis[5-methyl-8-(1-methylethyl)-3,10,17-trioxa-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione] - 10185 3.5.1.98 (8S,11S)-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),4,16(19)-tetraene-6,9,13-trione - 10186 3.5.1.98 (E)-3-(2-(((3-(1-benzylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)pyrimidin-5-yl)-N-hydroxyacrylamide 55% inhibition at 100 nM; 65% inhibition at 100 nM 237982 3.5.1.98 (E)-3-[3-[4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl]phenyl]-N-hydroxyacrylamide inhibitor for both EGFR/HER2 kinase and HDAC with potent cellular activity, i.e. target inhibition and cytotoxicity 19625 3.5.1.98 (E)-N-hydroxy-3-(2-(methyl((3-(1-(4-methylbenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)amino)pyrimidin-5-yl)acrylamide 60% inhibition at 100 nM; 61% inhibition at 100 nM 237983 3.5.1.98 (E)-N1-hydroxy-N5-(5-styryl-1,3,4-thiadiazol-2-yl)glutaramide antiproliferative activities against MDA-MB-231 and K562 cell lines, IC50 0.0059 and 0.00675 microM, respectively 55964 3.5.1.98 (S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-(4-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide - 83722 3.5.1.98 (S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-(naphthalen-1-yl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide - 83730 3.5.1.98 (S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-m-tolyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide - 83725 3.5.1.98 (S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-o-tolyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide - 83724 3.5.1.98 (S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-p-tolyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide - 83723 3.5.1.98 (S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-pentyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide - 83732 3.5.1.98 (S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-phenethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide - 83721 3.5.1.98 (S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-phenyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide hydrochloride - 83719 3.5.1.98 (S)-benzyl 3-(biphenyl-4-ylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate - 83737 3.5.1.98 (S)-benzyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(phenethylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate - 83735 3.5.1.98 (S)-benzyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(phenylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate - 83736 3.5.1.98 (S)-N-(2,4-dimethylphenyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide - 83728 3.5.1.98 (S)-N-(3-chloro-4-fluorophenyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide - 83729 3.5.1.98 (S)-N-(3-chlorophenyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide - 83727 3.5.1.98 (S)-N-(4-fluorophenyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide - 83726 3.5.1.98 (S)-N-(biphenyl-4-yl)-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide - 83731 3.5.1.98 (S)-N-benzyl-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide hydrochloride - 83720 3.5.1.98 (S)-N-hexyl-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide - 83733 3.5.1.98 (S)-N-tert -butyl-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide - 83734 3.5.1.98 (S)-tert-butyl 3-(2,4-dimethylphenylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate - 83712 3.5.1.98 (S)-tert-butyl 3-(3-chloro-4-fluorophenylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate - 83713 3.5.1.98 (S)-tert-butyl 3-(3-chlorophenylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate - 83711 3.5.1.98 (S)-tert-butyl 3-(4-fluorophenylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate - 83710 3.5.1.98 (S)-tert-butyl 3-(benzylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate - 83704 3.5.1.98 (S)-tert-butyl 3-(biphenyl-4-ylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate - 83715 3.5.1.98 (S)-tert-butyl 3-(hexylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate - 83717 3.5.1.98 (S)-tert-butyl 3-(tert-butylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate - 83718 3.5.1.98 (S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(4-methoxyphenylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate - 83706 3.5.1.98 (S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(mtolylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate - 83709 3.5.1.98 (S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(naphthalen-1-ylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate - 83714 3.5.1.98 (S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(o-tolylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate - 83708 3.5.1.98 (S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(p-tolylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate - 83707 3.5.1.98 (S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(pentylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate - 83716 3.5.1.98 (S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(phenethylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate - 83705 3.5.1.98 (S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(phenylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate - 83703 3.5.1.98 1,10-phenanthroline 10 mM, 66% inhibition 62 3.5.1.98 1-methyl-N-[(1S)-7-oxo-1-[(4-phenyl-1,3-thiazol-2-yl)carbamoyl]octyl]piperidine-2-carboxamide - 72909 3.5.1.98 1-[5-(2,3-dihydro-1,4-benzodioxin-6-yl)thiophen-2-yl]-2,2,2-trifluoroethanone - 28075 3.5.1.98 1-[5-(4-acetylphenyl)thiophen-2-yl]-2,2,2-trifluoroethanone - 28069 3.5.1.98 15-deoxy-DELTA12,14-prostaglandin J2-biotin maximal inhibition of recombinant HDAC3 in complex with CoR1 is 50% 83702 3.5.1.98 2,2,2-trifluoro-1-(2-phenyl-1,3-thiazol-5-yl)ethanone - 28076 3.5.1.98 2,2,2-trifluoro-1-(4-phenylthiophen-2-yl)ethanone - 28064 3.5.1.98 2,2,2-trifluoro-1-(5-phenylthiophen-2-yl)ethanone - 28063 3.5.1.98 2,2,2-trifluoro-1-(5-[3-[(methylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl]thiophen-2-yl)ethanone potent inhibitor of HDAC4 and shows more than 100fold selectivity overHDAC1 27660 3.5.1.98 2,2,2-trifluoro-1-(5-[3-[(propylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl]thiophen-2-yl)ethanone - 27685 3.5.1.98 2,2,2-trifluoro-1-(5-[3-[(thiophen-2-ylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl]thiophen-2-yl)ethanone - 27656 3.5.1.98 2,2,2-trifluoro-1-[5-(1H-indol-5-yl)thiophen-2-yl]ethanone - 28074 3.5.1.98 2,2,2-trifluoro-1-[5-(2-methoxyphenyl)thiophen-2-yl]ethanone - 28067 3.5.1.98 2,2,2-trifluoro-1-[5-(3-methoxyphenyl)thiophen-2-yl]ethanone - 28066 3.5.1.98 2,2,2-trifluoro-1-[5-(3-methyl-1,2,4-oxadiazol-5-yl)thiophen-2-yl]ethanone HDAC4-selective inhibitor 150496 3.5.1.98 2,2,2-trifluoro-1-[5-(3-[[(4-fluorobenzyl)sulfonyl]methyl]-1,2,4-oxadiazol-5-yl)thiophen-2-yl]ethanone - 27688 3.5.1.98 2,2,2-trifluoro-1-[5-(4-methoxyphenyl)thiophen-2-yl]ethanone - 28065 3.5.1.98 2,2,2-trifluoro-1-[5-(pyridin-2-yl)thiophen-2-yl]ethanone - 28072 3.5.1.98 2,2,2-trifluoro-1-[5-(quinoxalin-6-yl)thiophen-2-yl]ethanone - 28073 3.5.1.98 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluorooctanedioic acid (3,4-dimethylphenyl)-amide hydroxyamide - 17587 3.5.1.98 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluorooctanedioic acid biphenyl-2-ylamide hydroxyamide - 19415 3.5.1.98 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluorooctanedioic acid hydroxyamide (4-phenylthiazol-2-yl)amide - 17668 3.5.1.98 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluorooctanedioic acid hydroxyamide phenyl-amide competitive. Significant but rather unselective inhibition of cellular HDACs 19624 3.5.1.98 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluorooctanedioic acid hydroxyamide phenylamide - 204865 3.5.1.98 2,3-dihydrobenzoic acid 98% residual activity at 0.5 mM 163475 3.5.1.98 2-(((3-(1-(2,4-difluorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide 66% inhibition at 100 nM; 88% inhibition at 100 nM 238101 3.5.1.98 2-(((3-(1-(2-chloro-4-fluorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide 49% inhibition at 100 nM; 73% inhibition at 100 nM 238102 3.5.1.98 2-(((3-(1-(2-chlorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide 55% inhibition at 100 nM; 93% inhibition at 100 nM 238103 3.5.1.98 2-(((3-(1-(2-fluorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide 44% inhibition at 100 nM; 84% inhibition at 100 nM 238104 3.5.1.98 2-(((3-(1-(4-cyanobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide 38% inhibition at 100 nM; 68% inhibition at 100 nM 238105 3.5.1.98 2-(((3-(1-(4-fluorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide 65% inhibition at 100 nM; 92% inhibition at 100 nM 238106 3.5.1.98 2-(((3-(1-benzylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide 63% inhibition at 100 nM; 96% inhibition at 100 nM 238107 3.5.1.98 2-(3,6-dihydroxy-9H-xanthen-9-yl)-5-(8-(hydroxyamino)-8-oxooctanamido)benzoic acid synthesis, overview 206570 3.5.1.98 2-(3,6-dihydroxy-9H-xanthen-9-yl)-5-(8-methoxy-8-oxooctanamido)benzoic acid synthesis, overview 206569 3.5.1.98 2-(4-((3-(1-benzylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxyacetamide 18% inhibition at 100 nM; 35% inhibition at 100 nM 238135 3.5.1.98 2-(5-methoxy-2-methyl-1H-indol-3-yl)-N-[(1S)-7-oxo-1-(5-phenyl-1H-imidazol-2-yl)nonyl]acetamide - 14533 3.5.1.98 2-(5-methoxy-2-methyl-1H-indol-3-yl)-N-[(1S)-7-oxo-1-(5-phenyl-1H-imidazol-2-yl)octyl]acetamide - 10058 3.5.1.98 2-hydroxybutyric acid 96% residual activity at 0.5 mM 15496 3.5.1.98 2-[(methylsulfonyl)sulfanyl]ethanaminium bromide - 75585 3.5.1.98 2-[(methylsulfonyl)sulfanyl]ethyl 2-propylpentanoate - 75582 3.5.1.98 3,4-Dihydroxyphenyl acetic acid 90% residual activity at 0.5 mM 8263 3.5.1.98 3-(1-methyl-4-phenylacetyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide APHA 151861 3.5.1.98 3-(4-((3-(1-(2,4-difluorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxyacrylamide 35% inhibition at 100 nM; 74% inhibition at 100 nM 238270 3.5.1.98 3-(4-((3-(1-(2-chlorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxyacrylamide 59% inhibition at 100 nM; 8% inhibition at 100 nM 238271 3.5.1.98 3-(4-((3-(1-(2-cyanobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxyacrylamide 36% inhibition at 100 nM; 65% inhibition at 100 nM 238272 3.5.1.98 3-(4-((3-(1-(2-fluorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxyacrylamide 31% inhibition at 100 nM; 68% inhibition at 100 nM 238273 3.5.1.98 3-(4-((3-(1-(3,4-difluorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxyacrylamide 17% inhibition at 100 nM; 60% inhibition at 100 nM 238274 3.5.1.98 3-(4-((3-(1-(3-fluorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxyacrylamide 35% inhibition at 100 nM; 73% inhibition at 100 nM 238275 3.5.1.98 3-(4-((3-(1-(4-bromobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxyacrylamide 58% inhibition at 100 nM; 6% inhibition at 100 nM 238276 3.5.1.98 3-(4-((3-(1-(4-fluorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxyacrylamide 38% inhibition at 100 nM; 75% inhibition at 100 nM 238277 3.5.1.98 3-(4-((3-(1-allylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxyacrylamide 34% inhibition at 100 nM; 66% inhibition at 100 nM 238278 3.5.1.98 3-(4-((3-(1-allylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxypropanamide 15% inhibition at 100 nM; 4% inhibition at 100 nM 238279 3.5.1.98 3-(4-((3-(1-benzylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N- hydroxypropanamide 11% inhibition at 100 nM; 22% inhibition at 100 nM 238280 3.5.1.98 3-(4-((3-(1-benzylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxyacrylamide 35% inhibition at 100 nM; 71% inhibition at 100 nM 238281 3.5.1.98 3-benzoylbenzoic acid and hydroxamate analogs 151854 3.5.1.98 3-benzoylpropanoic acid and hydroxamate analogs 151856 3.5.1.98 3-hydroxycinnamic acid 96% residual activity at 0.5 mM 8432 3.5.1.98 3-[5-(trifluoroacetyl)thiophen-2-yl]benzoic acid the inhibitor shows 40fold selectivity for HDAC4 and 180fold for HDAC6 against HDAC1 28071 3.5.1.98 3-[5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2-(2-phenylethyl)-1H-benzimidazol-1-yl]propanoic acid - 73221 3.5.1.98 3-[5-[4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl]furan-2-yl]-N-hydroxy-acrylamide inhibitor for both EGFR/HER2 kinase and HDAC with potent cellular activity, i.e. target inhibition and cytotoxicity 19657 3.5.1.98 4-((3-(1-benzylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)-N-hydroxybenzamide 29% inhibition at 100 nM; 66% inhibition at 100 nM 238444 3.5.1.98 4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 2-propylpentanoate - 75581 3.5.1.98 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide M344 151862 3.5.1.98 4-benzoylbutyric acid and hydroxamate analogs 151855 3.5.1.98 4-benzoylbutyric hydroxamic acid - 75551 3.5.1.98 4-hydroxy-2-nonenal maximal inhibition of recombinant HDAC3 in complex with CoR1 is 70% 1426 3.5.1.98 4-phenylbutyric acid and hydroxamate analogs 12375 3.5.1.98 4-[5-(trifluoroacetyl)thiophen-2-yl]benzoic acid - 28070 3.5.1.98 4-[5-(trifluoroacetyl)thiophen-2-yl]benzonitrile - 28068 3.5.1.98 4-[[(2E)-2-(2-chlorobenzylidene)hydrazinyl]carbonothioyl]-N-hydroxypiperazine-1-carboxamide - 162351 3.5.1.98 4-[[(2E)-2-(4-chlorobenzylidene)hydrazinyl]carbonothioyl]-N-hydroxypiperazine-1-carboxamide inactivates HDAC8 preferentially over HDAC1 82425 3.5.1.98 4-[[(2E)-2-(anthracen-9-ylmethylidene)hydrazinyl]carbonothioyl]-N-hydroxypiperazine-1-carboxamide - 162341 3.5.1.98 5-(4-benzyl-1H-1,2,3-triazol-1-yl)-N-hydroxypentanamide - 151864 3.5.1.98 5-(4-hydroxyphenyl)-3H-1,2-dithiol-3-thione - 75580 3.5.1.98 5-phenylvaleric acid and hydroxamate analogs 51432 3.5.1.98 5-phenylvaleric hydroxamic acid - 75550 3.5.1.98 6-mercapto-N-phenylhexanamide - 63511 3.5.1.98 6-[(1-(mercaptomethyl)vinyl)amino]-N-phenylhexanamide - 63510 3.5.1.98 6-[(2E)-2-[(2-bromo-4-hydroxy-5-methoxyphenyl)methylidene]hydrazino]-N-hydroxy-6-oxohexanamide - 73444 3.5.1.98 6-[(2E)-2-[(2-bromo-4-hydroxyphenyl)methylidene]hydrazino]-N-hydroxy-6-oxohexanamide - 73445 3.5.1.98 6-[(2E)-2-[(2-bromo-5-hydroxyphenyl)methylidene]hydrazino]-N-hydroxy-6-oxohexanamide - 73446 3.5.1.98 6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanoic acid - 7003 3.5.1.98 6-[(9H-fluoren-3-ylmethyl)(3-phenoxybenzyl)amino]-N-hydroxyhexanamide simultaneous and efficient interactions of compound with both the enzyme surface and the tubular binding pocket, through proper selection of its arm groups, are critical for potential antagonist activity 33213 3.5.1.98 6-[(9H-fluoren-3-ylmethyl)(3-phenoxybenzyl)amino]-N-hydroxyhexanamide - 33213 3.5.1.98 6-[(biphenyl-4-ylmethyl)[4-[(4-bromobenzyl)oxy]benzyl]amino]-N-hydroxyhexanamide - 47161 3.5.1.98 6-[4-(2,6-dimethoxyphenyl)-1H-1,2,3-triazol-1-yl]-N-hydroxyhexanamide - 75568 3.5.1.98 6-[4-(biphenyl-2-yl)-1H-1,2,3-triazol-1-yl]-N-hydroxyhexanamide - 75573 3.5.1.98 6-[4-(biphenyl-3-yl)-1H-1,2,3-triazol-1-yl]-N-hydroxyhexanamide - 75571 3.5.1.98 6-[4-(biphenyl-4-yl)-1H-1,2,3-triazol-1-yl]-N-hydroxyhexanamide - 75570 3.5.1.98 6-[[4-[(4-bromobenzyl)oxy]benzyl](9H-fluoren-3-ylmethyl)amino]-N-hydroxyhexanamide - 49745 3.5.1.98 6-{4-[4-(dimethylamino)phenyl]-1H-1,2,3-triazol-1-yl}-N-hydroxyhexanamide - 75558 3.5.1.98 7-mercapto-N-(2-phenyl-1,3-thiazol-5-yl)heptanamide - 63517 3.5.1.98 7-mercapto-N-(3-phenoxyphenyl)heptanamide - 63514 3.5.1.98 7-mercapto-N-phenylheptanamide thiol formed by enzymatic hydrolysis in the cell reacts with the zinc ion in the active site of histone deacetylase. Molecular modeling of complex with histone HDAC8 36695 3.5.1.98 7-mercapto-N-pyridin-3-ylheptanamide - 63515 3.5.1.98 7-mercapto-N-quinolin-3-ylheptanamide - 63516 3.5.1.98 7-[(2E)-2-[(2-bromo-4-hydroxy-5-methoxyphenyl)methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide - 73450 3.5.1.98 7-[(2E)-2-[(2-bromo-5-hydroxyphenyl)methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide - 73451 3.5.1.98 7-[(2E)-2-[(2-bromo-5-methoxyphenyl)methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide - 73452 3.5.1.98 7-[(2E)-2-[(2-bromophenyl)methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide - 73453 3.5.1.98 7-[(2E)-2-[(2-bromopyridin-3-yl)methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide - 73454 3.5.1.98 7-[(2E)-2-[(2-chlorophenyl)methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide - 73455 3.5.1.98 7-[(2E)-2-[(6-bromo-1,3-benzodioxol-5-yl)methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide - 72492 3.5.1.98 7-[(2E)-2-[[4-(dimethylamino)-2-hydroxyphenyl]methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide - 73456 3.5.1.98 7-[4-(biphenyl-3-yl)-1H-1,2,3-triazol-1-yl]-N-hydroxyheptanamide - 75572 3.5.1.98 7-{4-[4-(dimethylamino)phenyl]-1H-1,2,3-triazol-1-yl}-N-hydroxyheptanamide - 75559 3.5.1.98 8-hydroxyquinoline 85% residual activity at 0.5 mM 321 3.5.1.98 8-[(2E)-2-[(2,5-dihydroxyphenyl)methylidene]hydrazino]-N-hydroxy-8-oxooctanamide - 73464 3.5.1.98 acetylated histone deacetylase 1 the activity of HDAC2 is inhibited by acetylated HDAC1 163466 3.5.1.98 allyl mercaptan garlic organosulfur compounds can be metabolized to allyl mercaptan 30644 3.5.1.98 alpha-keto-gamma-methylselenobutyrate causes dose-dependent inhibition of HDAC activity, HDAC1 shows about 80% residual activity at 2 mM, HDAC8 shows less than 60% residual activity at 2 mM 96121 3.5.1.98 apicidin - 3563 3.5.1.98 apicidin natural inhibitor 3563 3.5.1.98 apicidin A - 151851 3.5.1.98 azumamide A - 75549 3.5.1.98 azumamide E - 151858 3.5.1.98 Baclofen 98% residual activity at 0.5 mM 20134 3.5.1.98 belinostat PXD101 151865 3.5.1.98 belinostat i.e. PXD-101; i.e. PXD-101 151865 3.5.1.98 beta-methylselenopyruvate causes dose-dependent inhibition of HDAC activity, competitive inhibitor of HDAC8, HDAC1 shows about 30% residual activity at 2 mM, HDAC8 shows less than 30% residual activity at 2 mM 83701 3.5.1.98 Butyrate non-competitive 462 3.5.1.98 Butyrate - 462 3.5.1.98 Butyrate inhibition of histone deacetylase activity, resulting in prevention of interferon gamma-induced Janus kinase 1 activation, STAT1 phosphorylation, its nuclear translocation, and STAT1-dependent gene activation 462 3.5.1.98 Butyrate inhibition of histone deacetylases, results in down-regulation of HoxA9 expression 462 3.5.1.98 Butyrate class I-selective HDAC inhibitor 462 3.5.1.98 Butyric acid - 1556 3.5.1.98 caffeic acid 80% residual activity at 0.5 mM 426 3.5.1.98 chidamide - 205408 3.5.1.98 chlorogenic acid highly potent HDAC inhibitor, 40% residual activity at 0.5 mM 592 3.5.1.98 Cinnamic acid 95% residual activity at 0.5 mM 864 3.5.1.98 curcumin highly potent HDAC inhibitor, 52% residual activity at 0.5 mM 696 3.5.1.98 cyclo (N-O-methyl-L-tryptophanyl-L-isoleucinyl-D-pipecolinyl-L-2-amino-8-oxodecanoyl) i.e. apicidin, a cyclic tetrapeptide having broad-spectrum antiparasitic activity, inhibits the enzyme activity as well as the in vitro growth of Babesia parasites with an IC50 of 3.8 ng/ml 206571 3.5.1.98 D-(-)-quinic acid 96% residual activity at 0.5 mM 163473 3.5.1.98 dihydrocaffeic acid 86% residual activity at 0.5 mM 7185 3.5.1.98 EDTA 1 mM, 30 min, complete loss of activity. Zn2+, Mg2+, Mn2+ may restore activity 21 3.5.1.98 entinostat MS-275 151866 3.5.1.98 entinostat - 151866 3.5.1.98 ferulic acid 80% residual activity at 0.5 mM 452 3.5.1.98 FK-228 natural inhibitor 75548 3.5.1.98 FK-228 - 75548 3.5.1.98 FK228 - 151859 3.5.1.98 FOXP FOXP3 specifically inhibits binding of histone deacetylase 2 and 4 to the site and increases local histone H3 acetylation 163479 3.5.1.98 FR235222 - 151857 3.5.1.98 FR901228 Gal4-dHDAC1, consisting of the N-terminal 147 amino acid residues of the yeast Gal4 protein fused to the N terminus of full-length dHDAC1 protein, but not dHDAC1, is able to repress transcription in vitro. Transcriptional repression is blocked by the enzyme inhibitor FR901228 139218 3.5.1.98 FR901375 - 151852 3.5.1.98 gamma-aminobutyric acid - 7196 3.5.1.98 HC-toxin cyclic peptide inhibitor from Cochliobolus carbonum. Histone deacetylase in crude extracts of Alternaria brassicola is relatively insensitive to inhibition, such as enzyme from Cochliobolus carbonum. Comparison of sensitivity in various Cochliobolus carbonum strains and in several other fungi 25062 3.5.1.98 HC-toxin cyclic peptide inhibitor from Cochliobolus carbonum. Histone deacetylase in crude extracts of Cochliobolus carbonum is relatively insensitive to inhibition. Comparison of sensitivity in various Cochliobolus carbonum strains and in several other fungi. Resistance genetically cosegregates with toxin production 25062 3.5.1.98 HC-toxin cyclic peptide inhibitor from Cochliobolus carbonum. Histone deacetylase in crude extracts of Diheterospora chlamydosporia is relatively insensitive to inhibition, such as enzyme from Cochliobolus carbonum. Comparison of sensitivity in various Cochliobolus carbonum strains and in several other fungi 25062 3.5.1.98 HC-toxin - 25062 3.5.1.98 HDAC1 siRNA - 151860 3.5.1.98 indol-2-carboxylic acid 97% residual activity at 0.5 mM 163476 3.5.1.98 isobutyric acid 80% residual activity at 0.5 mM 11133 3.5.1.98 Isothiocyanate found in cruciferous vegetables 10681 3.5.1.98 ITF-2357 broad-spectrum or pan-HDAC inhibitor 75544 3.5.1.98 ITF-2357 - 75544 3.5.1.98 JNJ-26481585 broad-spectrum or pan-HDAC inhibitor 151847 3.5.1.98 K+ K+ bound to monovalent cation site 1 inhibits catalytic activity of HDAC8 (11fold less active with two K+ ions bound compared to one K+ ion bound), partial inhibition at high KCl 39 3.5.1.98 LAQ-824 - 151863 3.5.1.98 LAQ824 enzyme inhibition results in altered Toll-like receptor 4-dependent activation and function of macrophages and dendritic cells. Pan-HDAC inhibition modulates only a limited set of genes involved in distinct arms of immune responses, specifically dendritic cell-controlled T helper 1 effector, but not T helper 2 effector cell activation and migration. It also inhibits dendritic cell-mediated monocyte, but not neutrophil chemotaxis 18437 3.5.1.98 LAQ824 - 18437 3.5.1.98 LAQ824 pan-HDAC inhibitor 18437 3.5.1.98 largazole - 18973 3.5.1.98 largazole FK228; FK228; FK228; FK228 18973 3.5.1.98 LBH-589 panobinostat, broad-spectrum or pan-HDAC inhibitor 26694 3.5.1.98 LBH-589 - 26694 3.5.1.98 LBH589 - 26696 3.5.1.98 LBH589 pan-histone deacetylase inhibitor 26696 3.5.1.98 Mandelic acid 85% residual activity at 0.5 mM 5573 3.5.1.98 MC1568 specificity for class II HDACs; specificity for class II HDACs; specificity for class II HDACs; specificity for class II HDACs; specificity for class II HDACs 18975 3.5.1.98 MC1575 specificity for class II HDACs; specificity for class II HDACs; specificity for class II HDACs; specificity for class II HDACs; specificity for class II HDACs 18974 3.5.1.98 MC1863 - 151868 3.5.1.98 MCP30 30 kDa protein isolated from bitter melon seeds, Momordica charantia, contains two highly related type I ribosome-inactivating proteins, alpha- and beta-momorcharin 151849 3.5.1.98 methyl (3R,6R,9R)-9-(acetylamino)-6-[6-(hydroxyamino)-6-oxohexyl]-5,8-dioxo-4,7-diazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3-carboxylate tight binding competitive inhibition 18325 3.5.1.98 methyl N-[(2S)-2-[(N-acetyl-L-alanyl)amino]-7-(hydroxyamino)-7-oxoheptanoyl]-L-phenylalaninate - 36696 3.5.1.98 MGCD 290 an enzyme Hos2 inhibitor, for use in combination with azoles, such as fluconazole, for fungal infections 206567 3.5.1.98 MGCD-0103 mocetinostat dihydrobromide, class I-selective HDAC inhibitor 75545 3.5.1.98 MGCD-0103 - 75545 3.5.1.98 mocetinostat - 205464 3.5.1.98 additional information in phosphate buffer, the presence of NaCl is inhibitory 2 3.5.1.98 additional information isoform HDAC10 is resistant to inhibitors trapoxin B and sodium butyrate 2 3.5.1.98 additional information enzyme is part of a high molecular weight complex insensitive to trichostatin A 2 3.5.1.98 additional information when A-549 cells are stretched for 24 h cytoplasmic HDAC activity is decreased 2 3.5.1.98 additional information nitration of distinct tyrosine residues; nitrative/oxidative stress reduce HDAC2 expression via nitration of distinct tyrosine residues. Peroxynitrite, hydrogen peroxide and cigarette smoke-conditioned medium reduce HDAC2 expression in A549 epithelial cells in vitro. This reduction is due to increased proteasomal degradation following ubiquitination rather than reduction of mRNA expression or stability 2 3.5.1.98 additional information HDAC is not inhibited by isovaleric acid, L-valine, sodium lactate, succinic acid, citric acid, benzylic acid, hippuric acid, antranilic acid (2-aminobenzoic acid), alpha-hydroxyacetonaphthone, and kojic acid 2 3.5.1.98 additional information methylselenocysteine and selenomethionine have little or no inhibitory activity up to 2 mM 2 3.5.1.98 additional information the CDK-related kinase 3-associated HDAC activities are sensitive to the class I/II HDAC inhibitor trichostatin A and to the sirtuin inhibitor nicotinamide 2 3.5.1.98 additional information 3-[5-(trifluoroacetyl)thiophen-2-yl]benzoic acid shows no inhibition of HDAC1 at 0.01 mM, 2,2,2-trifluoro-1-[5-(pyridin-2-yl)thiophen-2-yl]ethanone is inactive against HDAC6, 2,2,2-trifluoro-1-[5-(1H-indol-5-yl)thiophen-2-yl]ethanone is essentially inactive against HDAC1 and 4 2 3.5.1.98 additional information HDAC10 is not inhibited by SK7068, MS275, and oxamflatin 2 3.5.1.98 additional information presence of 5-6 carbon units between the Zn2+ binding group and the 1,3,4-thiadiazole ring is optimal for inhibitory potency 2 3.5.1.98 additional information enzyme binding mechanisms, overview 2 3.5.1.98 additional information enzyme binding mechanisms, overview; enzyme binding mechanisms, overview; enzyme binding mechanisms, overview 2 3.5.1.98 additional information pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response, structure-activity and structure-property relationships for trans-3,4-disubstituted pyrrolidine inhibitors, overview. No inhibition by (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2-hydroxyethyl)pyrrolidine-3-carboxamide and (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2-hydroxy-2-methylpropyl)pyrrolidine-3-carboxamide 2 3.5.1.98 additional information pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response, structure-activity and structure-property relationships for trans-3,4-disubstituted pyrrolidine inhibitors, overview 2 3.5.1.98 additional information determination of structure-activity and structure-kinetic relationships of a series of selective ortho-aminoanilide inhibitors of histone deacetylase isozymes (HDACs) 1 and 2, overview. Measurements of increases in neuronal histone acetylation in mouse fore-brain primary neuronal cultures induced by HDAC inhibitor compounds. Analysis of the stability of the compounds in murine plasma and liver microsomes; determination of structure-activity and structure-kinetic relationships of a series of selective ortho-aminoanilide inhibitors of histone deacetylase isozymes (HDACs) 1 and 2, overview. Measurements of increases in neuronal histone acetylation in mouse fore-brain primary neuronal cultures induced by HDAC inhibitor compounds. Analysis of the stability of the compounds in murine plasma and liver microsomes; determination of structure-activity and structure-kinetic relationships of a series of selective ortho-aminoanilide inhibitors of histone deacetylase isozymes (HDACs) 1 and 2, overview. Measurements of increases in neuronal histone acetylation in mouse fore-brain primary neuronal cultures induced by HDAC inhibitor compounds. Analysis of the stability of the compounds in murine plasma and liver microsomes 2 3.5.1.98 additional information series of HDAC inhibitors, using 1,2,4-oxadiazole-containing as the cap group, are synthesized and evaluated in vitro, inhibitory effects and inhibition of diverse cancer cells, overview. Pharmacokinetic studies. Most HDAC inhibitors always have three parts: a cap group used as a selective vector, a ZBG group to bind with the Zn2+ ion, and a linker region that traditionally allows the ZBG group stretch into the catalytic binding; series of HDAC inhibitors, using 1,2,4-oxadiazole-containing as the cap group, are synthesized and evaluated in vitro, inhibitory effects and inhibition of diverse cancer cells, overview. Pharmacokinetic studies. Most HDAC inhibitors always have three parts: a cap group used as a selective vector, a ZBG group to bind with the Zn2+ ion, and a linker region that traditionally allows the ZBG group stretch into the catalytic binding 2 3.5.1.98 MS-275 inhibition of histone deacetylases, results in down-regulation of HoxA9 expression 2694 3.5.1.98 MS-275 - 2694 3.5.1.98 MS-275 SNDX-275, entinostat, class I-selective HDAC inhibitor 2694 3.5.1.98 MS-275 inhibition of HDAC1 leads to a significant increase of global acetylation of residues K9 and K14 on histone H3, which is a feature of active transcription, and a significant induction of proinflammatory cytokine expression. Genomic DNA corresponding to the IL1beta and IL6 promoter is significantly enriched upon HDAC 1 inhibition 2694 3.5.1.98 MS-275 56.3% inhibition at 0.01 mM, 46.3% inhibition at 0.001 mM 2694 3.5.1.98 N-(2-aminophenyl)-4-[[(4-biphenyl-4-yl-6-oxo-1,6-dihydropyrimidin-2-yl)sulfanyl]methyl]benzamide - 150692 3.5.1.98 N-(2-aminophenyl)-4-[[(6-oxo-4-phenyl-1,6-dihydropyrimidin-2-yl)sulfanyl]methyl]benzamide - 150693 3.5.1.98 N-(2-aminophenyl)-5-[(4-biphenyl-4-yl-6-oxo-1,6-dihydropyrimidin-2-yl)sulfanyl]pentanamide - 150694 3.5.1.98 N-(2-aminophenyl)-5-[(6-oxo-4-phenyl-1,6-dihydropyrimidin-2-yl)sulfanyl]pentanamide - 150695 3.5.1.98 N-(2-aminophenyl)-6-(4-biphenyl-4-yl-6-oxo-1,6-dihydropyrimidin-2-yl)hexanamide - 150369 3.5.1.98 N-(2-aminophenyl)-6-(6-oxo-4-phenyl-1,6-dihydropyrimidin-2-yl)hexanamide - 150696 3.5.1.98 N-(2-aminopyridin-3-yl)-5-[(6-oxo-4-phenyl-1,6-dihydropyrimidin-2-yl)sulfanyl]pentanamide - 150697 3.5.1.98 N-(2-hydroxyphenyl)-5-[(6-oxo-4-phenyl-1,6-dihydropyrimidin-2-yl)sulfanyl]pentanamide - 150699 3.5.1.98 N-(4-amino-3'-fluoro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide - 238781 3.5.1.98 N-(4-amino-4'-chloro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide - 238782 3.5.1.98 N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3,4-dihydro-1H-2-benzopyran-3-carboxamide - 238783 3.5.1.98 N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3,4-dihydro-2H-1-benzopyran-3-carboxamide - 238784 3.5.1.98 N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3-oxabicyclo[3.1.0]hexane-6-carboxamide - 238785 3.5.1.98 N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-3-carboxamide - 238786 3.5.1.98 N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide i.e. BRD4884, coordinates to the Zn2+ ion via the free aniline -NH2, completing its tetrahedral coordination sphere in addition to the side chains of Asp181, His183, and Asp269 with the anilide carbonyl oxygen situated at a distance of 2.8 A to the Zn2+ ion. The anilide-NH of BRD4884 forms an H-bond to the backbone carbonyl oxygen of Gly154. The 11 A lipophilic channel harbors the tetrahydropyran moiety of BRD4884 making Van Der Waals contacts with the channel wall. The tetrahydropyran ring adopts a preferential chair conformation allowing the pyran oxygen atom to form a hydrogen bond (3.5 A) with a conserved water at the surface of HDAC2, inhibition kinetics; i.e. BRD4884, possesses kinetic selectivity for isozyme HDAC1 versus HDAC2, inhibition kinetics; inhibition kinetics 238787 3.5.1.98 N-(4-aminopyrimidin-5-yl)-5-[(6-oxo-4-phenyl-1,6-dihydropyrimidin-2-yl)sulfanyl]pentanamide - 150346 3.5.1.98 N-(4-amino[1,1'-biphenyl]-3-yl)oxane-4-carboxamide - 238788 3.5.1.98 N-(6-mercaptohexyl)-1-benzofuran-2-carboxamide - 63519 3.5.1.98 N-(6-mercaptohexyl)-1H-indole-2-carboxamide - 63520 3.5.1.98 N-(6-mercaptohexyl)-2-naphthamide - 63518 3.5.1.98 N-(6-mercaptohexyl)benzamide - 63512 3.5.1.98 N-(8,8,8-trifluoro-7-oxooctyl)benzamide - 238806 3.5.1.98 N-(8-aminonaphthalen-1-yl)-5-[(4-biphenyl-4-yl-6-oxo-1,6-dihydropyrimidin-2-yl)sulfanyl]pentanamide - 150704 3.5.1.98 N-(8-aminonaphthalen-1-yl)-5-[(6-oxo-4-phenyl-1,6-dihydropyrimidin-2-yl)sulfanyl]pentanamide - 150705 3.5.1.98 N-(8-aminonaphthalen-1-yl)-6-(4-biphenyl-4-yl-6-oxo-1,6-dihydropyrimidin-2-yl)hexanamide - 150706 3.5.1.98 N-(8-aminonaphthalen-1-yl)-6-(6-oxo-4-phenyl-1,6-dihydropyrimidin-2-yl)hexanamide - 150707 3.5.1.98 N-biphenyl-3-yl-7-mercaptoheptanamide - 63513 3.5.1.98 N-hydroxy-1-(3-hydroxypropyl)-2-(2-phenylethyl)-1H-benzimidazole-5-carboxamide - 73668 3.5.1.98 N-hydroxy-1-methyl-indole-6-carboxamide HDAC8-selective inhibitor 39094 3.5.1.98 N-hydroxy-2-(methyl((3-(1-(3-methylbenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)amino)pyrimidine-5-carboxamide 54% inhibition at 100 nM; 93% inhibition at 100 nM 238829 3.5.1.98 N-hydroxy-2-(methyl((3-(1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)amino)pyrimidine-5-carboxamide 30% inhibition at 100 nM; 62% inhibition at 100 nM 238830 3.5.1.98 N-hydroxy-2-(methyl((3-(1-(4-methylbenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)amino)pyrimidine-5-carboxamide 71% inhibition at 100 nM; 96% inhibition at 100 nM 238831 3.5.1.98 N-hydroxy-2-[1-methyl-2-(2-phenylethyl)-1H-benzimidazol-5-yl]cyclopropanecarboxamide - 73669 3.5.1.98 N-hydroxy-3-(4-((3-(1-(2-methylbenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)acrylamide 14% inhibition at 100 nM; 68% inhibition at 100 nM 238838 3.5.1.98 N-hydroxy-3-(4-((3-(1-(2-nitrobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)acrylamide 19% inhibition at 100 nM; 63% inhibition at 100 nM 238839 3.5.1.98 N-hydroxy-3-(4-((3-(1-(3-methylbenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)acrylamide 25% inhibition at 100 nM; 73% inhibition at 100 nM 238840 3.5.1.98 N-hydroxy-3-(4-((3-(1-(4-methoxybenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)acrylamide 36% inhibition at 100 nM; 75% inhibition at 100 nM 238841 3.5.1.98 N-hydroxy-3-(4-((3-(1-(4-methylbenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)acrylamide 32% inhibition at 100 nM; 76% inhibition at 100 nM 238842 3.5.1.98 N-hydroxy-3-(4-((3-(1-(4-methylbenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)propanamide 12% inhibition at 100 nM; 28% inhibition at 100 nM 238843 3.5.1.98 N-hydroxy-3-(4-((3-(1-propylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)acrylamide 40% inhibition at 100 nM; 69% inhibition at 100 nM 238844 3.5.1.98 N-hydroxy-3-(4-((3-(1-propylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)propanamide 13% inhibition at 100 nM; 5% inhibition at 100 nM 238845 3.5.1.98 N-hydroxy-3-[1-(3-hydroxypropyl)-2-(2-methylpropyl)-1H-benzimidazol-5-yl]propanamide - 73670 3.5.1.98 N-hydroxy-3-[2-(2-phenylethyl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazol-5-yl]propanamide - 73671 3.5.1.98 N-hydroxy-3-[2-[(2-methyl-1H-indol-3-yl)acetyl]-2,3-dihydro-1H-isoindol-5-yl]propanamide anti-proliferative activity in human HCT116 cell line, IC50 0.19 microM 61101 3.5.1.98 N-hydroxy-4-(methyl[(5-pyridin-2-yl-2-thienyl)sulfonyl]amino)benzamide - 24615 3.5.1.98 N-hydroxy-4-[[(2E)-2-(2-hydroxybenzylidene)hydrazinyl]carbonothioyl]piperazine-1-carboxamide inactivates HDAC8 preferentially over HDAC1 81845 3.5.1.98 N-hydroxy-4-[[(2E)-2-(4-methylbenzylidene)hydrazinyl]carbonothioyl]piperazine-1-carboxamide - 162414 3.5.1.98 N-hydroxy-4-[[(2Z)-2-(2-oxo-1,2-dihydro-3H-indol-3-ylidene)hydrazinyl]carbonothioyl]piperazine-1-carboxamide - 162326 3.5.1.98 N-hydroxy-4-{[5-(propan-2-yl)naphthalene-1-sulfonyl]amino}butanamide - 205604 3.5.1.98 N-hydroxy-5-(4-phenyl-1H-1,2,3-triazol-1-yl)pentanamide - 75555 3.5.1.98 N-hydroxy-5-{[5-(propan-2-yl)naphthalene-1-sulfonyl]amino}pentanamide - 205605 3.5.1.98 N-hydroxy-6-(4-phenyl-1H-1,2,3-triazol-1-yl)hexanamide - 75556 3.5.1.98 N-hydroxy-6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanamide - 7004 3.5.1.98 N-hydroxy-6-[(3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-1,4,7,11-tetraoxotetradecahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecin-3-yl]hexanamide - 10200 3.5.1.98 N-hydroxy-6-[4-(2-methoxyphenyl)-1H-1,2,3-triazol-1-yl]hexanamide - 75567 3.5.1.98 N-hydroxy-6-[4-(3-methoxyphenyl)-1H-1,2,3-triazol-1-yl]hexanamide - 75566 3.5.1.98 N-hydroxy-6-[4-(3-methylphenyl)-1H-1,2,3-triazol-1-yl]hexanamide - 39097 3.5.1.98 N-hydroxy-6-[4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl]hexanamide - 75565 3.5.1.98 N-hydroxy-6-[4-(4-methylphenyl)-1H-1,2,3-triazol-1-yl]hexanamide - 75564 3.5.1.98 N-hydroxy-6-[4-(6-methoxynaphthalen-2-yl)-1H-1,2,3-triazol-1-yl]hexanamide - 75576 3.5.1.98 N-hydroxy-6-[4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl]hexanamide - 75562 3.5.1.98 N-hydroxy-6-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]hexanamide - 75560 3.5.1.98 N-hydroxy-6-[4-(pyridin-4-yl)-1H-1,2,3-triazol-1-yl]hexanamide - 75561 3.5.1.98 N-hydroxy-6-[4-(quinolin-2-yl)-1H-1,2,3-triazol-1-yl]hexanamide - 75578 3.5.1.98 N-hydroxy-6-[4-(quinolin-7-yl)-1H-1,2,3-triazol-1-yl]hexanamide - 75579 3.5.1.98 N-hydroxy-6-[4-(thiophen-2-yl)-1H-1,2,3-triazol-1-yl]hexanamide - 75569 3.5.1.98 N-hydroxy-6-{4-[4-(pyridin-4-yl)phenyl]-1H-1,2,3-triazol-1-yl}hexanamide - 75574 3.5.1.98 N-hydroxy-6-{[5-(propan-2-yl)naphthalene-1-sulfonyl]amino}hexanamide - 205607 3.5.1.98 N-hydroxy-7-(4-phenyl-1H-1,2,3-triazol-1-yl)heptanamide - 75557 3.5.1.98 N-hydroxy-7-[(2E)-2-[(2-hydroxynaphthalen-1-yl)methylidene]hydrazino]-7-oxoheptanamide - 73675 3.5.1.98 N-hydroxy-7-[(2E)-2-[(3-hydroxyphenyl)methylidene]hydrazino]-7-oxoheptanamide - 71136 3.5.1.98 N-hydroxy-7-[(2E)-2-[[4-(1H-imidazol-1-yl)phenyl]methylidene]hydrazino]-7-oxoheptanamide - 73676 3.5.1.98 N-hydroxy-7-[4-(6-methoxynaphthalen-2-yl)-1H-1,2,3-triazol-1-yl]heptanamide - 75577 3.5.1.98 N-hydroxy-7-[4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl]heptanamide - 75563 3.5.1.98 N-hydroxy-7-{4-[4-(pyridin-4-yl)phenyl]-1H-1,2,3-triazol-1-yl}heptanamide - 75575 3.5.1.98 N-hydroxy-7-{[5-(propan-2-yl)naphthalene-1-sulfonyl]amino}heptanamide - 205608 3.5.1.98 N-hydroxy-8-oxo-8-[(2E)-2-[(2,4,6-trihydroxyphenyl)methylidene]hydrazino]octanamide - 73677 3.5.1.98 N-hydroxy-8-{[5-(propan-2-yl)naphthalene-1-sulfonyl]amino}octanamide - 205609 3.5.1.98 N-hydroxy-N~3~-[5-(propan-2-yl)naphthalene-1-sulfonyl]-beta-alaninamide - 205638 3.5.1.98 N-hydroxynaphthalene-1-carboxamide HDAC8-selective inhibitor 73678 3.5.1.98 N-methyl-N-(quinoxalin-6-ylmethyl)-5-(trifluoroacetyl)thiophene-2-carboxamide - 27666 3.5.1.98 N-[(1S)-1-(6-chloro-1H-benzimidazol-2-yl)-7-oxooctyl]-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide - 10201 3.5.1.98 N-[(2E)-3-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]prop-2-en-1-yl]-2-sulfanylacetamide - 10202 3.5.1.98 N-[(3E)-4-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]but-3-en-1-yl]-2-sulfanylacetamide - 10225 3.5.1.98 N-[1,1,2,2,3,3,4,4,5,5,6,6-dodecafluoro-7-(hydroxyamino)-7-oxoheptyl]benzamide a highly selective hydroxamate inhibitor 238993 3.5.1.98 N-[2-amino-5-(pyridin-3-yl)phenyl]oxane-4-carboxamide - 239012 3.5.1.98 N-[2-amino-5-(pyridin-4-yl)phenyl]oxane-4-carboxamide - 239013 3.5.1.98 N-[4-amino-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]oxane-4-carboxamide - 239029 3.5.1.98 N1-(5-benzyl-1,3,4-thiadiazol-2-yl)-N7-hydroxyheptanediamide antiproliferative activities against MDA-MB-231 and K562 cell lines, IC50 0.0061 and 0.0122 microM, respectively 56610 3.5.1.98 N1-(5-benzyl-1,3,4-thiadiazol-2-yl)-N8-hydroxyoctanediamide antiproliferative activities against MDA-MB-231 and K562 cell lines, IC50 0.00298 and 0.0091 microM, respectively 56569 3.5.1.98 N1-hydroxy-N7-(5-phenyl-1,3,4-thiadiazol-2-yl)heptanediamide antiproliferative activities against MDA-MB-231 and K562 cell lines, IC50 0.0055 and 0.0129 microM, respectively 57473 3.5.1.98 N1-hydroxy-N8-(5-phenyl-1,3,4-thiadiazol-2-yl)octanediamide - 56570 3.5.1.98 N1-methyl-2-oxo-N9-phenylnonanediamide - 63509 3.5.1.98 NaCl inhibitory in sodium phosphate/citric acid buffer, 50% inhibition at 100 mM 42 3.5.1.98 NVP-LAQ824 - 163477 3.5.1.98 oxamflatin - 39095 3.5.1.98 p300 p300 can inactivate HDAC6 by acetylation 75554 3.5.1.98 panobinostat LBH-589 163471 3.5.1.98 panobinostat - 163471 3.5.1.98 panobinostat i.e. LBH-589; i.e. LBH-589 163471 3.5.1.98 PAOA - 151867 3.5.1.98 PCI-24781 broad-spectrum or pan-HDAC inhibitor 151846 3.5.1.98 PCI-34051 HDAC8-selective inhibitor 75546 3.5.1.98 peroxynitrite activity of wild-type enzyme is reduced to 38% in presence of peroxynitrite. Activities of mutants Y153A and Y253A are 233 completely abolished in the presence of peroxynitrite. Mutant Y146A shows 32% reduction in activity 1220 3.5.1.98 phenyl butyric acid - 83739 3.5.1.98 phenylbutyrate Buphenyl 20805 3.5.1.98 phenylbutyric acid - 23238 3.5.1.98 propionic acid 80% residual activity at 0.5 mM 1724 3.5.1.98 PXD-101 belinostat, broad-spectrum or pan-HDAC inhibitor 75543 3.5.1.98 PXD-101 - 75543 3.5.1.98 PXD101 - 163478 3.5.1.98 pyridin-3-ylmethyl (4-[[(2-aminophenyl)amino]carbonyl]benzyl)carbamate i.e. MS27-275 24616 3.5.1.98 R306465 - 163472 3.5.1.98 resminostat - 205844 3.5.1.98 romidepsin FK228 39093 3.5.1.98 romidepsin FK-228, FR901228, depsipeptide, class I-selective HDAC inhibitor 39093 3.5.1.98 romidepsin i.e. FK-228; i.e. FK-228 39093 3.5.1.98 S-(2-hydroxyethyl) methanesulfonothioate - 75584 3.5.1.98 S-nitrosocysteine the activity of HDAC8 is significantly inhibited when incubated with S-nitrosoglutathione and S-nitrosocysteine in a time- and dosage-dependent manner. Sodium nitroprusside and dithiothreitol cannot reverse this inhibition 8516 3.5.1.98 S-nitrosoglutathione HDAC8 can be S-nitrosylated by S-nitrosoglutathione in vitro, and the activity of HDAC8 is significantly inhibited when incubated with S-nitrosoglutathione and S-nitrosocysteine in a time- and dosage-dependent manner. Sodium nitroprusside and dithiothreitol cannot reverse this inhibition 980 3.5.1.98 S-[2-[(2-propylpentanoyl)amino]ethyl]methanesulfonothioate - 75583 3.5.1.98 S-[7-oxo-7-(2-phenyl1,3-thiazol-5-ylamino)heptyl] 2-methylpropanethioate analysis of growth inhibition of various cancer cells and comparison with suberoylanilide hydroxamic acid 138145 3.5.1.98 SAHA - 151869 3.5.1.98 SAHA i.e. vorinostat; i.e. vorinostat 151869 3.5.1.98 salicylic acid 92% residual activity at 0.5 mM 765 3.5.1.98 SB-939 - 163470 3.5.1.98 scriptaid - 163467 3.5.1.98 shRNA - 4411 3.5.1.98 siRNA - 772 3.5.1.98 SK7041 i.e. 4-dimethylamino-N-[4-(2-hydroxylcarbamoyl-vinyl)benzyl] benzamide 163469 3.5.1.98 sodium butyrate - 6098 3.5.1.98 sodium butyrate pan-HDAC inhibitor 6098 3.5.1.98 sodium phenylbutyrate - 83738 3.5.1.98 sorbic acid 91% residual activity at 0.5 mM 32413 3.5.1.98 spiruchostatin - 151853 3.5.1.98 splitomicin - 75552 3.5.1.98 suberoyl anilide hydroxamic acid - 41261 3.5.1.98 suberoylanilide hydroxamic acid - 1547 3.5.1.98 suberoylanilide hydroxamic acid inhibition of histone deacetylase activity, resulting in prevention of interferon gamma-induced Janus kinase 1 activation, STAT1 phosphorylation, its nuclear translocation, and STAT1-dependent gene activation 1547 3.5.1.98 suberoylanilide hydroxamic acid SAHA 1547 3.5.1.98 suberoylanilide hydroxamic acid SAHA, vorinostat, zolinza, broad-spectrum or pan-HDAC inhibitor 1547 3.5.1.98 suberoylanilide hydroxamic acid SAHA, synthetic inhibitor 1547 3.5.1.98 suberoylanilide hydroxamic acid SAHA, vorinostat 1547 3.5.1.98 suberoylanilide hydroxamic acid SAHA; SAHA; SAHA; SAHA; SAHA 1547 3.5.1.98 suberoylanilide hydroxamic acid pan-HDAC inhibitor 1547 3.5.1.98 suberoylanilide hydroxamic acid i.e. SAHA, antiproliferative activities against MDA-MB-231 and K562 cell lines, IC50 0.00132 and 0.00169 microM, respectively 1547 3.5.1.98 suberoylanilide hydroxamic acid complete inhibition; complete inhibition 1547 3.5.1.98 suberoylanilide hydroxamic acid SAHA, Ki, for the T-cell lymphoma drug suberoylanilide hydroxamic acid (SAHA) is different for each metal-substituted HDAC8 1547 3.5.1.98 suberoylanilide hydroxyamic acid a specific inhibitor of zinc-dependent histone deacetylase activity. The compound directly induces p19INK4d expression in regenerating liver by increasing p19INK4d promoter-associated histone acetylation, molecular mechanisms by which the inhibitor delays liver regeneration exerting promoter-specific effects on histone acetylation during liver regeneration, overview 206568 3.5.1.98 suberoylanilide trifluoromethylketone - 205847 3.5.1.98 sulforaphane at 0.015 mM, 40, 30 and 40% inhibition of histone deacetylase activities in BPH-1, LnCaP and PC-3 prostate epithelial cells, resp. Inhibition is accompanied by a 50-100% increase in acetylated histones. BPH-1 cells treated with inhibitor show enhanced interaction of acetylated histone H4 with the promoter region of the P21 gene and the bax gene 6941 3.5.1.98 sulforaphane SFN, found in broccoli sprouts 6941 3.5.1.98 tartaric acid 90% residual activity at 0.5 mM 21214 3.5.1.98 trapoxin - 37046 3.5.1.98 trapoxin A - 151850 3.5.1.98 trapoxin B natural inhibitor 75547 3.5.1.98 trapoxin B - 75547 3.5.1.98 trichostatin A - 1314 3.5.1.98 trichostatin A inhibition of histone deacetylase activity, resulting in prevention of interferon gamma-induced Janus kinase 1 activation, STAT1 phosphorylation, its nuclear translocation, and STAT1-dependent gene activation 1314 3.5.1.98 trichostatin A inhibition of histone deacetylases, results in down-regulation of HoxA9 expression 1314 3.5.1.98 trichostatin A TSA 1314 3.5.1.98 trichostatin A natural inhibitor 1314 3.5.1.98 trichostatin A TSA; TSA; TSA; TSA; TSA 1314 3.5.1.98 trichostatin A TSA, a HDAC inhibitor; TSA, a HDAC inhibitor 1314 3.5.1.98 trichostatin-A specific HDAC inhibitor 28077 3.5.1.98 trichostatin-A specific HDAC inhibitor; specific HDAC inhibitor; specific HDAC inhibitor 28077 3.5.1.98 trichostatinA TSA, treatment with the specific HDAC inhibitor induces the enzyme HDA1, effectively inhibits AhHDA1 activity 247558 3.5.1.98 troglitazone - 3139 3.5.1.98 tubacin HDAC6-selective inhibitor 26695 3.5.1.98 tubacin - 26695 3.5.1.98 Valeric acid 83% residual activity at 0.5 mM 4577 3.5.1.98 Valproate class I-selective HDAC inhibitor 6032 3.5.1.98 Valproic acid treatment causes hyperacetylation of histones in cultured cells and activates transcription from diverse exogenous and endogenous promoters 2424 3.5.1.98 Valproic acid - 2424 3.5.1.98 Valproic acid Depakene, Convulex 2424 3.5.1.98 vorinostat SAHA 7817 3.5.1.98 vorinostat - 7817 3.5.1.98 [4-[(E)-[[6-(hydroxyamino)-6-oxohexanoyl]hydrazono]methyl]phenyl]boronic acid - 75553